From EGFR PTM network to TKI resistance: spatial subtypes and targeting in lung cancer

Abstract

Lung cancer represents the most prevalent and lethal malignancy worldwide. Although tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR) demonstrate clinical efficacy, the emergence of resistance remains a major therapeutic obstacle. This review comprehensively examines how six key post-translational modifications (PTMs) of EGFR - phosphorylation, palmitoylation, ubiquitination, glycosylation, acetylation, and S-nitrosylation - collectively govern its signaling dynamics, protein turnover, and subcellular trafficking. Based on this mechanistic framework, we propose a novel classification of resistance subtypes: membrane-retained, degradation-evading, nuclear-localized, and mitochondrial-localized EGFR, each defined by distinct PTM signatures and spatial localization. Furthermore, we analyze the intricate crosstalk among these PTMs, revealing hierarchical and often cooperative relationships that ultimately determine the fate and function of EGFR. Our analysis suggests that targeting specific spatial PTM hubs or their interactive networks, rather than EGFR alone, offers a promising strategy to overcome resistance. We also emphasize the need to integrate multi-PTM profiling with spatial proteomics to inform precision combination therapies. This work proposes a shift in the therapeutic paradigm from mere kinase inhibition toward reprogramming the pathological PTM network underlying resistant lung cancer.

Keywords

Lung cancer / EGFR / TKI resistance / spatial PTM / subcellular trafficking / degradation

References

[1] Thai AA,Sequist LV,Heist RS.Lung cancer.Lancet2021;398:535-54

[2] Bajbouj K,Ramakrishnan RK,Hamid Q.Histone modification in NSCLC: molecular mechanisms and therapeutic targets.Int J Mol Sci2021;22:11701 PMCID:PMC8584007

[3] Moldovanu D,van der Aalst CM.Lung cancer screening and smoking cessation efforts.Transl Lung Cancer Res2021;10:1099-109 PMCID:PMC7947402

[4] Li Q,Tang Y.A novel prognostic signature based on smoking-associated genes for predicting prognosis and immune microenvironment in NSCLC smokers.Cancer Cell Int2024;24:171 PMCID:PMC11094918

[5] Zhang Y,Duan FG.p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling.Cancer Cell Int2019;19:188 PMCID:PMC6642601

[6] Lim TKH,Kerr KM.KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing.Lung Cancer2023;184:107293

[7] Harrison PT,Huang PH.Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.Semin Cancer Biol2020;61:167-79 PMCID:PMC7083237

[8] Dong RF,Liu MM.EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research.Pharmacol Res2021;167:105583

[9] Ramírez Moreno M, Bulgakova NA. The cross-talk between EGFR and E-Cadherin.Front Cell Dev Biol2021;9:828673 PMCID:PMC8811214

[10] He Q,Bao H.Multiple post-translational modifications ensure EGFR functionality: potential therapeutic targets to overcome its drug-resistance mutations.Cytokine Growth Factor Rev2023;70:41-53

[11] Zhang J,Li M.Overcoming EGFR-TKI resistance by targeting the tumor microenvironment.Chin Med J Pulm Crit Care Med2024;2:151-61 PMCID:PMC11471126

[12] Zhang X,Ross KE.Alterations in the global proteome and phosphoproteome in third generation EGFR TKI resistance reveal drug targets to circumvent resistance.Cancer Res2021;81:3051-66 PMCID:PMC8182571

[13] Huang KY,Wang WL.Small molecule T315 promotes Casitas B-lineage lymphoma-dependent degradation of epidermal growth factor receptor via Y1045 autophosphorylation.Am J Respir Crit Care Med2016;193:753-66

[14] Wang C,Chen W,Xing D.Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: a review.Biochim Biophys Acta Rev Cancer2023;1878:188927

[15] Hong X,Tseng TY.Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.J Biol Chem2023;299:104814 PMCID:PMC10276293

[16] Zhang S,Li C.MCAM interacts with integrin β1 to promote EGFR-TKI resistance in lung adenocarcinoma through the JAK3 signalling pathway.J Transl Med2025;23:831 PMCID:PMC12291482

[17] Tong J,Peterman SM,Moran MF.Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041.Mol Cell Proteomics2009;8:2131-44 PMCID:PMC2742444

[18] Guo H,Ren S.Targeting EGFR-dependent tumors by disrupting an ARF6-mediated sorting system.Nat Commun2022;13:6004 PMCID:PMC9556547

[19] Shen CH,Lai TY.ZNRF1 mediates epidermal growth factor receptor ubiquitination to control receptor lysosomal trafficking and degradation.Front Cell Dev Biol2021;9:642625 PMCID:PMC8118649

[20] Lam D, Arroyo B, Liberchuk AN, Wolfe AL. Effects of N361 glycosylation on epidermal growth factor receptor biological function. bioRxiv 2024;2024.07.12.603279. PMCID:PMC11275927

[21] Liu W,Zhou X,Avner ED.HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells.PLoS One2012;7:e49418 PMCID:PMC3496684

[22] Switzer CH,Cheng RY.S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer.Mol Cancer Res2012;10:1203-15 PMCID:PMC3463231

[23] Gao YS,Yao TP.The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation.J Biol Chem2010;285:11219-26 PMCID:PMC2856999

[24] Runkle KB,Stypulkowski E.Inhibition of DHHC20-mediated EGFR palmitoylation creates a dependence on EGFR signaling.Mol Cell2016;62:385-96 PMCID:PMC4860254

[25] Ali A,Teo JT.Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.EMBO Mol Med2018;10:e8313 PMCID:PMC5840543

[26] Bollu LR,Blessing AM.Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation.Oncotarget2015;6:34992-5003 PMCID:PMC4741504

[27] Sato K.Cellular functions regulated by phosphorylation of EGFR on Tyr845.Int J Mol Sci2013;14:10761-90 PMCID:PMC3709701

[28] Clift CL,Mehta A.Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.Anal Bioanal Chem2021;413:2709-19 PMCID:PMC8012227

[29] Ardito F,Perrone D,Lo Muzio L.The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).Int J Mol Med2017;40:271-80 PMCID:PMC5500920

[30] Halder S,Lall SP,Batra SK.Targeting the EGFR signaling pathway in cancer therapy: what’s new in 2023?.Expert Opin Ther Targets2023;27:305-24 PMCID:PMC10330690

[31] Kim CL,Kim K,Mo JS.Phosphorylation analysis of the Hippo-YAP pathway using Phos-tag.J Proteomics2022;261:104582

[32] Singh V,Kumar R,Roy BK.Phosphorylation: implications in cancer.Protein J2017;36:1-6

[33] Del Piccolo N, Hristova K. Quantifying the interaction between EGFR dimers and Grb2 in live cells.Biophys J2017;113:1353-64 PMCID:PMC5607047

[34] Shi H,Yi Y.Inhibition of the Ras-ERK pathway in mitotic COS7 cells is due to the inability of EGFR/Raf to transduce EGF signaling to downstream proteins.Oncol Rep2016;35:3593-9

[35] Wang D,Meng Y,Ye Z.The configuration of GRB2 in protein interaction and signal transduction.Biomolecules2024;14:259 PMCID:PMC10968029

[36] Du Y,Wang WK,Boopathy GTK.Cracking the EGFR code: cancer biology, resistance mechanisms, and future therapeutic frontiers.Pharmacol Rev2025;77:100076

[37] Wee P.Epidermal growth factor receptor cell proliferation signaling pathways.Cancers2017;9:52 PMCID:PMC5447962

[38] Sun Q,Ng C,Sivaraman J.Additional serine/threonine phosphorylation reduces binding affinity but preserves interface topography of substrate proteins to the c-Cbl TKB domain.PLoS One2010;5:e12819 PMCID:PMC2943896

[39] Hartman Z,Agazie YM.HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling.Oncogene2013;32:4169-80 PMCID:PMC3538112

[40] Wang P,Zhou R.Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium.Redox Biol2024;69:102976 PMCID:PMC10746566

[41] Iida M,Campbell DA,Wheeler DL.Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.Oncogene2013;32:759-67 PMCID:PMC3381861

[42] Atwell B,Schroeder J.Nuclear epidermal growth factor receptor as a therapeutic target.Explor Target Antitumor Ther2023;4:616-29 PMCID:PMC10501894

[43] An Z,Zheng T,Weiss WA.Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.Oncogene2018;37:1561-75 PMCID:PMC5860944

[44] Pham L,Wan J.Regulation of mitochondrial oxidative phosphorylation through tight control of cytochrome c oxidase in health and disease - Implications for ischemia/reperfusion injury, inflammatory diseases, diabetes, and cancer.Redox Biol2024;78:103426 PMCID:PMC11617887

[45] Kwak SM,Hwang JT.EGFR-c-Src-mediated HDAC3 phosphorylation exacerbates invasion of breast cancer cells.Cells2019;8:930 PMCID:PMC6721651

[46] Che TF,Wu YY.Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC.Oncotarget2015;6:37349-66 PMCID:PMC4741934

[47] Font-Mateu J,Sot J.A progesterone derivative linked to a stable phospholipid activates breast cancer cell response without leaving the cell membrane.Cell Mol Life Sci2024;81:98 PMCID:PMC10884080

[48] Daveri E,Alfine E,Oteiza PI.Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway.Redox Biol2021;38:101830 PMCID:PMC7750420

[49] Kohale IN,Zhuang Y.Identification of Src family kinases as potential therapeutic targets for chemotherapy-resistant triple negative breast cancer.Cancers2022;14:4220 PMCID:PMC9454481

[50] Ma Y,Li J,Li Y.Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer.Front Cell Dev Biol2024;12:1436033 PMCID:PMC11703921

[51] Martellucci S,Sabetta S,Botta L.Src family kinases as therapeutic targets in advanced solid tumors: what we have learned so far.Cancers2020;12:1448 PMCID:PMC7352436

[52] Zhou B,Zhang L.The palmitoylation of AEG-1 dynamically modulates the progression of hepatocellular carcinoma.Theranostics2022;12:6898-914 PMCID:PMC9576614

[53] Zhu J,Chen Z.Inhibiting S-palmitoylation arrests metastasis by relocating Rap2b from plasma membrane in colorectal cancer.Cell Death Dis2024;15:675 PMCID:PMC11401852

[54] Zhou B,Liang Y.Protein palmitoylation in cancer: molecular functions and therapeutic potential.Mol Oncol2023;17:3-26 PMCID:PMC9812842

[55] Ma Y,Wei A.Enhancing Gpx1 palmitoylation to inhibit angiogenesis by targeting PPT1.Redox Biol2024;77:103376 PMCID:PMC11532489

[56] Lv K,Han X,Gong C.Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression.Blood2021;138:2244-55 PMCID:PMC8832469

[57] Zhang Q,Zhou W.ZDHHC1 downregulates LIPG and inhibits colorectal cancer growth via IGF2BP1 Palmitoylation.Cancer Gene Ther2024;31:1427-37 PMCID:PMC11405259

[58] Jia Y,Park E.Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.Nature2016;534:129-32 PMCID:PMC4929832

[59] Kharbanda A,Gudiel AA,Feldser DM.Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.Sci Signal2020;13:eaax2364 PMCID:PMC7310254

[60] Bollu LR,Blessing AM.Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells.Cell Cycle2014;13:2415-30 PMCID:PMC4128886

[61] Wang TH,Huang KY.Profiling of subcellular EGFR interactome reveals hnRNP A3 modulates nuclear EGFR localization.Oncogenesis2020;9:40 PMCID:PMC7176650

[62] Chaturvedi S,Sadhukhan S.Identification of selective plant-derived natural carotenoid and flavonoids as the potential inhibitors of DHHC-mediated protein S-palmitoylation: an in silico study.J Biomol Struct Dyn2025;43:5110-23

[63] U.S. FOOD & DRUG Administration. Orlistat (marketed as Alli and Xenical) information. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/orlistat-marketed-alli-and-xenical-information. [Last accessed on 2 Mar 2026].

[64] Shao G,Sun A.The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.Mol Cancer2018;17:24 PMCID:PMC5817799

[65] Singh S,Wang YT.PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target.Cell Death Dis2023;14:671 PMCID:PMC10567730

[66] Awan AB,Khan OM.Ubiquitination enzymes in cancer, cancer immune evasion, and potential therapeutic opportunities.Cells2025;14:69 PMCID:PMC11763706

[67] Hong SY,Hsiao SH.Stabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma.Oncogene2022;41:1907-17

[68] Fu L,Zhang X.The functions and regulation of Smurfs in cancers.Semin Cancer Biol2020;67:102-16

[69] Wang X,Wu Y,Wang X.The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy.Front Immunol2023;14:1202633 PMCID:PMC10196180

[70] Shen J,Qi H,Shao J.JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation.Cell Death Dis2023;14:657 PMCID:PMC10562424

[71] Song F,Wang B.Weak binding to E3 ubiquitin ligase c-Cbl increases EGFRvA protein stability.FEBS Lett2016;590:1345-53

[72] Kim MS.Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells.PLoS One2025;20:e0320668 PMCID:PMC11960930

[73] Kim Y,Nakagawa T.Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma.Oncogene2018;37:5387-402

[74] Niño CA,Giangreco G,Polo S.USP25 regulates EGFR fate by modulating EGF-induced ubiquitylation dynamics.Biomolecules2020;10:1548 PMCID:PMC7696865

[75] Zhou J,Li W.Long noncoding RNA LINC01485 promotes tumor growth and migration via inhibiting EGFR ubiquitination and activating EGFR/Akt signaling in gastric cancer.Onco Targets Ther2020;13:8413-25 PMCID:PMC7457555

[76] Liu Y,Dong J.Targeted protein degradation via cellular trafficking of nanoparticles.Nat Nanotechnol2025;20:296-302

[77] Lin TY,Sun WH,Tsao SM.Induction of Cbl-dependent epidermal growth factor receptor degradation in Ling Zhi-8 suppressed lung cancer.Int J Cancer2017;140:2596-607

[78] Sirisaengtaksin N,Yan Q.UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation.J Biol Chem2014;289:3026-39 PMCID:PMC3908433

[79] Tabernero L.Dissecting the role of His domain protein tyrosine phosphatase/PTPN23 and ESCRTs in sorting activated epidermal growth factor receptor to the multivesicular body.Biochem Soc Trans2018;46:1037-46 PMCID:PMC6195633

[80] Tito C,Colotti G.EGF receptor in organ development, tissue homeostasis and regeneration.J Biomed Sci2025;32:24 PMCID:PMC11837477

[81] Jeong CH.Inhibition of ubiquitin-specific peptidase 8 suppresses growth of gefitinib-resistant non-small cell lung cancer cells by inducing apoptosis.J Cancer Prev2015;20:57-63 PMCID:PMC4384715

[82] Eichler J.Protein glycosylation.Curr Biol2019;29:R229-31

[83] Lee JB,Kim HR.Role and function of O-GlcNAcylation in cancer.Cancers2021;13:5365 PMCID:PMC8582477

[84] Kaszuba K,Orłowski A.N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes.Proc Natl Acad Sci U S A2015;112:4334-9 PMCID:PMC4394299

[85] Yen HY,Chen NY.Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.Proc Natl Acad Sci U S A2015;112:6955-60 PMCID:PMC4460513

[86] Lindsey S.Epidermal growth factor signaling in transformed cells.Int Rev Cell Mol Biol2015;314:1-41 PMCID:PMC4888053

[87] Liu YC,Chen CY.Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells.Proc Natl Acad Sci U S A2011;108:11332-7 PMCID:PMC3136320

[88] Ankenbauer KE,Mattheyses AL.Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics.J Biol Chem2023;299:105217 PMCID:PMC10520885

[89] He X,von Itzstein M,Packer NH.Influence of an ER-retention signal on the N-glycosylation of recombinant human α-L-iduronidase generated in seeds of Arabidopsis.Plant Mol Biol2012;79:157-69

[90] He M,Wang X.Glycosylation: mechanisms, biological functions and clinical implications.Signal Transduct Target Ther2024;9:194 PMCID:PMC11298558

[91] Taylor ES,Lins RD.Conformational stability of the epidermal growth factor (EGF) receptor as influenced by glycosylation, dimerization and EGF hormone binding.Proteins2017;85:561-70 PMCID:PMC5835389

[92] Wu L,Geng D.O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling.Proc Natl Acad Sci U S A2022;119:e2107453119 PMCID:PMC8915906

[93] Xu S,Zhu Y.Stabilization of EREG via STT3B-mediated N-glycosylation is critical for PDL1 upregulation and immune evasion in head and neck squamous cell carcinoma.Int J Oral Sci2024;16:47 PMCID:PMC11214941

[94] Gc S,Rickenbacker L.α2,6 sialylation mediated by ST6GAL1 promotes glioblastoma growth.JCI Insight2022;7:e158799 PMCID:PMC9675560

[95] U.S. FOOD & DRUG Administration. Drugs@FDA: FDA-approved drugs. Approval history for Cisplatin (NDA #018057). Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018057. [Last accessed on 2 Mar 2026].

[96] Mehta KA,Kunnumakkara AB.Curbing the deregulation of glycosylation in tongue carcinoma cells with natural compounds.Anticancer Agents Med Chem2021;21:1717-23

[97] Manabe Y,Kasahara S.Development of a FUT8 inhibitor with cellular inhibitory properties.Angew Chem Int Ed Engl2024;63:e202414682

[98] He W,Li X.Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer.Biochim Biophys Acta Rev Cancer2023;1878:188837

[99] Bahl S,Acharige NPN,Pflum MKH.EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function.Cell Death Dis2021;12:469 PMCID:PMC8113371

[100] Ramazi S.Posttranslational modifications in proteins: resources, tools and prediction methods.Database2021;2021:baab012 PMCID:PMC8040245

[101] Song H,Labaff AM.Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors.Biochem Biophys Res Commun2011;404:68-73 PMCID:PMC3049249

[102] Varga JK,Welker Leng KR,Schueler-Furman O.Structure-based prediction of HDAC6 substrates validated by enzymatic assay reveals determinants of promiscuity and detects new potential substrates.Sci Rep2022;12:1788 PMCID:PMC8810773

[103] Wang Z,Hu P.HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.Oncol Rep2016;36:589-97

[104] Jo H,Jeoung D.Targeting HDAC6 to overcome autophagy-promoted anti-cancer drug resistance.Int J Mol Sci2022;23:9592 PMCID:PMC9455701

[105] Wen Y,Li Z.HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy.Cancer Immunol Immunother2024;73:7 PMCID:PMC10794344

[106] Caligiuri M,Castro J.FT-6876, a potent and selective inhibitor of CBP/p300, is active in preclinical models of androgen receptor-positive breast cancer.Target Oncol2023;18:269-85 PMCID:PMC10042772

[107] Lin W,Li XY,Zhao LQ.Nitric oxide regulates multiple signal pathways in plants via protein S-nitrosylation.Curr Issues Mol Biol2025;47:407 PMCID:PMC12192061

[108] Bignon E,Lucchetta M,Papaleo E.Computational structural biology of S-nitrosylation of cancer targets.Front Oncol2018;8:272 PMCID:PMC6102371

[109] Murillo-Carretero M,Castro C,Estrada C.S-nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity.Free Radic Biol Med2009;46:471-9

[110] Cho B,Chang E,Shin I.S-nitrosylation-triggered unfolded protein response maintains hematopoietic progenitors in Drosophila.Dev Cell2024;59:1075-90.e6

[111] Freedman BI,Cartwright K.Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II).Control Clin Trials1999;20:493-510

[112] Kawano M.[Aminoguanidine].Nihon Rinsho1997;55:221-4

[113] Li H,Chreifi G,Poulos TL.Structural basis for isoform selective nitric oxide synthase inhibition by thiophene-2-carboximidamides.Biochemistry2018;57:6319-25 PMCID:PMC6282162

[114] Isaac I,Tran N.Reengineering endogenous targeting lipid nanoparticles (ENDO) for systemic delivery of mRNA to pancreas.Adv Mater2025;37:e2507657 PMCID:PMC12510295

[115] Bhuia MS,Hasan R.Trans-ferulic acid antagonizes the anti-inflammatory activity of etoricoxib: possible interaction of COX-1 and NOS.Biotechnol Appl Biochem2025;72:1284-301

[116] Jones RB,Hjelmeland AB.The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling.J Biol Chem2018;293:5659-67 PMCID:PMC5900773

[117] Jameson NM,Benitez J.Intron 1-mediated regulation of EGFR expression in EGFR-dependent malignancies is mediated by AP-1 and BET proteins.Mol Cancer Res2019;17:2208-20 PMCID:PMC6825583

[118] Waudby CA,Josue Ruiz E.An intrinsic temporal order of c-JUN N-terminal phosphorylation regulates its activity by orchestrating co-factor recruitment.Nat Commun2022;13:6133 PMCID:PMC9576782

[119] Qi Z,Zhang J.PCSK9 (proprotein convertase subtilisin/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36.Circulation2021;143:45-61

[120] Funakoshi-Tago M,Sonoda Y,Kasahara T.TRAF6 and C-SRC induce synergistic AP-1 activation via PI3-kinase-AKT-JNK pathway.Eur J Biochem2003;270:1257-68

[121] Mertins P, Mani DR, Ruggles KV, et al; NCI CPTAC. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55-62. PMCID:PMC5102256

[122] Nishida N,Mori M.EGFR gets in the way of microRNA biogenesis.Cell Res2013;23:1157-8 PMCID:PMC3790241

[123] Shen J,Khotskaya YB.EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2.Nature2013;497:383-7 PMCID:PMC3717558

[124] Jiang Y,Zhu C.STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice.Sci Signal2023;16:eadd2282 PMCID:PMC10907978

[125] Yin J,Rhim J.Cross-talk between PARN and EGFR-STAT3 signaling facilitates self-renewal and proliferation of glioblastoma stem cells.Cancer Res2023;83:3693-709

[126] Xu X,Zhang C.Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence.Cell Death Dis2019;10:282 PMCID:PMC6433862

[127] Liu Y,Gu W.p53 modifications: exquisite decorations of the powerful guardian.J Mol Cell Biol2019;11:564-77 PMCID:PMC6736412

[128] Andonegui-Elguera S,Peña-Martínez E.The genomic landscape of corticotroph tumors: from silent adenomas to ACTH-secreting carcinomas.Int J Mol Sci2022;23:4861 PMCID:PMC9106092

[129] Ho TLF,Goh HC.Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities.Nat Commun2023;14:1726 PMCID:PMC10050071

[130] Kurcon T,Paradkar AV.miRNA proxy approach reveals hidden functions of glycosylation.Proc Natl Acad Sci U S A2015;112:7327-32 PMCID:PMC4466752

[131] Ryazansky S.Fraternity of old-timers: how ubiquitin regulates miRNA functions.Bioessays2023;45:e2200220

[132] Dunphy K,Bazou D.Current methods of post-translational modification analysis and their applications in blood cancers.Cancers2021;13:1930 PMCID:PMC8072572

[133] Ben-Chetrit N,Swett AD.Integration of whole transcriptome spatial profiling with protein markers.Nat Biotechnol2023;41:788-93 PMCID:PMC10272089